As the UK and Canada forge new trade links, CF has formed a strategic partnership with Medlior Health Outcomes Research. The collaboration aims to accelerate the generation of policy-grade real-world evidence for global life science sponsors, with data sets in England and Alberta.
The strategic alliance takes place under the Access Innovation BioBridge programme, a UK-Canada initiative. By running protocol-aligned analyses in both jurisdictions, the partnership will support cross-jurisdictional studies in key chronic disease areas focused on cardio renal metabolic conditions including a wide range of cardiovascular conditions, chronic kidney disease (CKD), and type 2 diabetes and obesity. The objective is to generate transportable insights to inform clinical development, market access, and health economics and outcomes research (HEOR).
Jaspreet Grewal, managing partner of the Access Innovation BioBridge Programme, commented, “The CF and Medlior partnership exemplifies exactly what the BioBridge programme was designed to achieve—bringing together world-class capabilities from both countries to create new pathways for life sciences innovation. By facilitating access to complementary healthcare datasets and regulatory frameworks, we’re helping to build the infrastructure that will drive the next generation of pharmaceutical research and development across UK-Canada corridors.”
CF is a consultancy specialising in the health and healthcare space. The firms works with leaders and frontline teams to improve health, transform healthcare, drive adoption of innovation and create value through investment, from offices in London, Riyadh and Dubai. It serves clients in the UK and across Europe and the Middle East.
By combining CF’s expertise in and access to NHS data from England with Medlior’s expertise in analysing Alberta’s comprehensive population-level administrative datasets, the partnership offers a robust and credible alternative to US-centric evidence generation, providing valuable input for global decision-making. The results will be delivered as comparable, aggregate outputs across both universal health systems, facilitating faster learning and improved decision-making.
Unlike many US data sources – often affected by coverage gaps, payor churn, and limited historical depth – CF and Medlior provide access to whole-population, cradle-to-grave linked health data including demographic data, diagnostic coding, activity data and costing data. This enables robust longitudinal tracking of disease progression, treatment patterns, and outcomes over extended time horizons – taking in NHS England data covering over 57 million people along with Medlior’s expertise accessing and analysing Alberta’s population-level provincial administrative datasets of over 5 million people.
Ben Richardson, managing partner or life sciences at CF, commented, “CF has a long history of using whole-population health data from the UK to improve outcomes and support research. By combining CF’s access to linked, pseudonymised NHS data with Medlior’s Alberta cohorts, we can address a critical question for sponsors: to what extent does evidence generated in one health system transport to another?”
The initial focus of this collaboration is on cardiovascular renal metabolic, including a wide range of cardiovascular conditions, chronic kidney disease (CKD), and type 2 diabetes and obesity to generate “transportable” insights for clinical development, market access, and HEOR. CF and Medlior have extensive experience and published findings in these areas. Both parties have the ability to capture data on hundreds of thousands to millions of people within the whole population, limited by practices in coding and availability of data.
Medlior President Tara Cowling added, “Our population-level cohorts, alongside Alberta’s comprehensive pharmacy data, complement CF’s UK platform – together we can deliver faster and deeper insights across borders to support decision-grade evidence needs.”
Source link
#partners #Medlior #Health #Outcomes #life #science #development #Canada
